Charles Herzog, MD
Cardiovascular Disease · Minneapolis, MNNPI 1417996588
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $140,496 of the $157,144 with a category attached, or 89.4%. 10 manufacturers reported payments, led by AstraZeneca at 33.2% of the total. Reporting peaked in 2020 at $45,707 and has fallen 79.8% since, to $9,245 in 2025. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $1227.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$52K
- Merck$36K
- Bayer$35K
- Novo Nordisk$7K
- Nxstage Medical, Inc.$7K
- Pfizer$6K
- plus $13K from 4 others
Across 3 payments — averaging $23,244 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vifor Pharma, Inc.$69K
- Amgen$652
What the payments were for
- Consulting fees$140,49689%
- Speaking & faculty fees$6,0004%
- Travel & lodging$8,0375%
- Food & beverage$2,6122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $52,113 |
| Merck | 18 | $35,904 |
| Bayer | 32 | $35,202 |
| Novo Nordisk | 1 | $7,065 |
| Nxstage Medical, Inc. | 21 | $7,065 |
| Pfizer | 2 | $6,350 |
| Amgen | 2 | $5,500 |
| Vifor Pharma, Inc. | 2 | $3,864 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,600 |
| Astrazeneca UK Limited | 5 | $481 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$42,427
- Kerendia$28,032
- Non-Covered$6,556
- ELIQUIS$6,350
- Repatha$5,500
- Veltassa$3,864
- System One$3,626
- NXSTAGE SYSTEM ONE$3,000
- FARXIGA$2,148
How this compares
$157,144 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Tamas AlexyMinneapolis$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.